Personalized Medicine in Localized Prostate Cancer: Are We There Yet?
Open Access
- 1 May 2022
- journal article
- editorial
- Published by Elsevier BV in International Journal of Radiation Oncology*Biology*Physics
- Vol. 113 (1), 77-79
- https://doi.org/10.1016/j.ijrobp.2022.02.001
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysisThe Lancet Oncology, 2022
- Dose Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Suppression for Intermediate Risk Prostate Cancer: Outcomes From the NRG Oncology/RTOG 0815 Randomized TrialInternational Journal of Radiation Oncology*Biology*Physics, 2021
- Prevalence of Missing Data in the National Cancer Database and Association With Overall SurvivalJAMA Network Open, 2021
- Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the ProstateJAMA Oncology, 2020
- Molecular Biomarkers in Localized Prostate Cancer: ASCO GuidelineJournal of Clinical Oncology, 2020
- Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy CohortJournal of Clinical Oncology, 2013
- Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective studyThe Lancet Oncology, 2011
- Use of Archived Specimens in Evaluation of Prognostic and Predictive BiomarkersJNCI Journal of the National Cancer Institute, 2009
- THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CANCER OF THE PROSTATE RISK ASSESSMENT SCORE: A STRAIGHTFORWARD AND RELIABLE PREOPERATIVE PREDICTOR OF DISEASE RECURRENCE AFTER RADICAL PROSTATECTOMYJournal of Urology, 2005